These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12151478)

  • 21. Glycoprotein inhibitors and fibrinolysis in myocardial infarction.
    Ring BL
    JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766
    [No Abstract]   [Full Text] [Related]  

  • 22. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiplatelet therapy for ischemic heart disease.
    Lange RA; Hillis LD
    N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 25. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 26. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction.
    Chaitman BR; Lim MJ
    J Am Coll Cardiol; 2004 Jul; 44(2):313-5. PubMed ID: 15261924
    [No Abstract]   [Full Text] [Related]  

  • 27. Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.
    Kereiakes DJ
    J Invasive Cardiol; 2009 Mar; 21(3):110-3. PubMed ID: 19258641
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 29. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue angioplasty after thrombolysis.
    Sharma S; Bhambi B; Nyitray W
    N Engl J Med; 2006 Apr; 354(15):1639-41; author reply 1639-41. PubMed ID: 16615182
    [No Abstract]   [Full Text] [Related]  

  • 31. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    Osman F; Qaisar S; El Gaylani N; Pitt M
    JAMA; 2005 Oct; 294(13):1616-7; author reply 1617-8. PubMed ID: 16204658
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 33. Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent.
    De Luca L; Sardella G
    JAMA; 2005 Oct; 294(13):1617; author reply 1617-8. PubMed ID: 16204659
    [No Abstract]   [Full Text] [Related]  

  • 34. Improving microvascular perfusion with platelet glycoprotein IIb/IIIa receptor inhibition.
    Dippel EJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():12E-16E; quiz 17E. PubMed ID: 12668858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 37. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

  • 38. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty.
    Zorman S; Zorman D; Noc M
    Am J Cardiol; 2002 Sep; 90(5):533-6. PubMed ID: 12208418
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter by Lin et al regarding article, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention".
    Lin GM; Chu KM; Han CL
    Circulation; 2010 Feb; 121(7):e43; author reply e44-5. PubMed ID: 20177003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.